Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...
Explore opportunities with Novartis below.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback